AstraZeneca Pharma India Ltd posted a 14.9% rise in second-quarter net profit for FY27, backed by sharp demand across its specialty cancer and rare disease portfolios.
Net earnings climbed to ₹62.3 crore for the quarter ended September, up from ₹54.2 crore in the corresponding period last fiscal, according to regulatory filings. Revenue from operations jumped 30.4% to ₹729 crore from ₹559 crore. The top-line run lifted cumulative revenue for the first half of FY27 to ₹1,411.9 crore, marking a 30% expansion over the previous financial year.
But profitability margins narrowed. Earnings before interest, tax, depreciation, and amortisation (EBITDA) rose 26.7% to ₹95 crore from ₹75 crore. Yet EBITDA margin contracted by 30 basis points to 13.1% compared to 13.4% a year earlier.
Market traders reacted swiftly to the margin trim. AstraZeneca Pharma India shares slid ₹79.90, or 1.26%, to settle at ₹6,285.20 on the BSE on Thursday.
| Financial Metric | Q2 FY27 | Q2 FY26 | YoY Change (%) |
|---|---|---|---|
| Revenue from Operations | ₹729.0 crore | ₹559.0 crore | +30.4% |
| EBITDA | ₹95.0 crore | ₹75.0 crore | +26.7% |
| EBITDA Margin | 13.1% | 13.4% | -30 bps |
| Net Profit | ₹62.3 crore | ₹54.2 crore | +14.9% |
Pipeline clearances during the quarter opened fresh revenue pathways. The drugmaker secured regulatory approvals for trastuzumab deruxtecan across three specific breast cancer settings. Regulators cleared the drug for adults with HER2-positive Stage II or III early breast cancer following taxane, trastuzumab, and pertuzumab therapies, as well as for patients presenting residual invasive disease after neoadjuvant care.
Further clearances cover trastuzumab deruxtecan paired with pertuzumab for first-line treatment of unresectable or metastatic HER2-positive breast cancer confirmed via immunohistochemistry 3+ or in situ hybridisation. In immunology, the company cleared benralizumab for patients aged 12 and above diagnosed with hypereosinophilic syndrome lacking non-haematologic secondary triggers.
Growth tracks deliberate capital allocation into high-barrier treatments. "The continued growth demonstrates the strength of AstraZeneca’s science-led portfolio and our ability to translate innovation into meaningful impact for patients in India," said Praveen Rao Akkinepally, Country President and Managing Director of AstraZeneca Pharma India Ltd. He noted that the company is stepping up execution across oncology, biopharmaceuticals, and rare diseases through broader healthcare distribution partnerships.
Commercial rollouts across these newly cleared indications will determine margin resilience through the second half of FY27.